Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein...

first-line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have a mutation in BRAF, and as a second-line treatment...

group using the vaccine, 44% in the vaccine and ipilimumab group, and 46% in the group treated with ipilimumab alone. However, some have raised concerns about...

immune function. Approved checkpoint inhibitors include antibodies such as ipilimumab, nivolumab, and pembrolizumab. Dendritic cell therapy provokes anti-tumor...

function. The first anti-cancer drug targeting an immune checkpoint was ipilimumab, a CTLA4 blocker approved in the United States in 2011. Currently approved...

Program. It is approved for use following treatment with ipilimumab, or after treatment with ipilimumab and a BRAF inhibitor in advanced melanoma patients who...

Treatment with pembrolizumab, atezolizumab, or combination nivolumab plus ipilimumab are all superior to chemotherapy alone against tumors expressing PD-L1...

combination with ipilimumab demonstrating an ORR of 44% in melanoma patients refractory to anti-PD1 therapy vs 10-13% response rate with ipilimumab monotherapy...

response to ipilimumab. The Phase III clinical failure of Pfizer's tremelimumab anti-CTLA-4 monoclonal antibody, which competed with ipilimumab, provided...

CTLA4 (cytotoxic T-lymphocyte-associated protein 4) inhibitors, such as ipilimumab. PD-1 and CTLA-4 are both expressed on activated T cells, but at different...

there are now multiple generic producers. Vumon (teniposide) Yervoy (ipilimumab) Psychiatry Abilify (aripiprazole comarketed with Otsuka Pharmaceutical)...

Therapies for metastatic melanoma include the biologic immunotherapy agents ipilimumab, pembrolizumab, and nivolumab; BRAF inhibitors, such as vemurafenib and...

chemotherapy. In the context of melanoma, certain treatments, such as Ipilimumab, result in high grade adverse events, or immune-related adverse events...

Therapies for metastatic melanoma include the biologic immunotherapy agents ipilimumab, pembrolizumab, and nivolumab; BRAF inhibitors, such as vemurafenib and...

antibody. Nivolumab and Pembrolizumab are anti PD-1 monoclonal antibodies. Ipilimumab is a monoclonal antibody that targets Cytotoxic T-lymphocyte-associated...

checkpoint therapies". This work ultimately led to the clinical development of ipilimumab (Yervoy), which was approved in 2011 by the FDA for the treatment of metastatic...

antibody. Nivolumab and Pembrolizumab are anti PD-1 monoclonal antibodies. Ipilimumab is a monoclonal antibody that targets Cytotoxic T-lymphocyte-associated...

Tyrosine kinase inhibitors (e.g. sunitinib), checkpoint inhibitors (e.g. ipilimumab, nivolumab, pembrolizumab, atezolizumab) Contrast agent Gadolininum based...

Howerver, the KEYNOTE-598 phase III trial has reported in 2021 that adding ipilimumab to pembrolizumab for NSCLC patients with PD-L1 tumor proportion score...

Cephem-type antibiotics cefazolin -mab Monoclonal antibodies trastuzumab, ipilimumab -ximab Chimeric antibody, in which the design of the therapeutic antibody...

name Opdivo, Bristol-Myers Squibb) is in phase III/IV clinical trials Ipilimumab (brand name Yervoy, Bristol-Myers Squibb) is in phase II clinical trials...

"Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors". ClinicalTrials.gov. Retrieved...

include: Alemtuzumab Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab Rituximab Trastuzumab...

Treatments for metastatic melanoma include biologic immunotherapy agents ipilimumab, pembrolizumab, nivolumab, cemiplimab; BRAF inhibitors, such as vemurafenib...

century, the clinical use of immune checkpoint blocking antibodies such as ipilimumab or pembrolizumab has greatly increased the number of abscopally responding...

effects. When compared with combinations of immunotherapy (nivolumab and ipilimumab), sunitinib may lead to more progression and serious effects. There may...

Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab...

ClinicalTrials.gov. 2 June 2020. Retrieved 7 August 2020. "A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer". ClinicalTrials.gov. 12 February 2018. Retrieved...

recently, the FDA has approved a combination therapy with both anti-CTLA4 (ipilimumab) and anti-PD1 (nivolumab) in October 2015. The molecular factors and receptors...

October 2020, the FDA approved the combination of nivolumab (Opdivo) with ipilimumab (Yervoy) for the first-line treatment of adults with malignant pleural...